Across TCGA pan-cancer cohorts, IGHV1-69 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV1-69 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGHV1-69 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV1-69 expression acts as an unfavorable survival marker.

HNSC and LUAD are the cancer types where IGHV1-69 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.170	0.696	.010	18	view →
LUAD	OS	Median	All	0.254	0.697	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IGHV1-69 tumor-vs-normal RNA expression · all IGHV1-69 data types